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Abstract
Background: Right ventricular (RV) dysfunction is a complication of pulmonary hypertension and portends a poor
prognosis. Pharmacological therapies targeting RV function in pulmonary hypertension may reduce symptoms, improve
hemodynamics, and potentially increase survival. We hypothesize that recombinant human angiotensin-converting enzyme
2 (rhACE2) will improve RV function in a pressure overload model.
Results: rhACE2 administered at 1.8 mg/kg/day improved RV systolic and diastolic function in pulmonary artery banded
mice as measured by in vivo hemodynamics. Specifically, rhACE2 increased RV ejection fraction and decreased RV end
diastolic pressure and diastolic time constant (p,0.05). In addition, rhACE2 decreased RV hypertrophy as measured by RV/
LV+S ratio (p,0.05). There were no significant negative effects of rhACE2 administration on LV function. rhACE2 had no
significant effect on fibrosis as measured by trichrome staining and collagen1a1 expression. In pulmonary artery banded
mice, rhACE2 increased Mas receptor expression and normalized connexin 37 expression.
Conclusion: In a mouse RV load-stress model of early heart failure, rhACE2 diminished RV hypertrophy and improved RV
systolic and diastolic function in association with a marker of intercellular communication. rhACE2 may be a novel treatment
for RV failure.
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Introduction
Pulmonary hypertension (PH) is a broad term describing any
elevation in mean pulmonary artery pressure greater than
25 mmHg at rest as determined by right heart catheterization.
PH is caused by a variety of diseases including pulmonary arterial
hypertension (PAH), PH secondary to left-sided heart disease, PH
associated with lung disease and/or hypoxia, and PH resulting
from chronic thrombotic/embolic disease [1]. Despite diverse
etiologies, all categories of PH share right ventricular (RV)
function as a critical determinant of morbidity and mortality [2,3].
Importantly, RV dysfunction in PH can be reversible. For
example, RV function improves after lung transplantation for
PAH and after pulmonary endarterectomy in patients with
chronic thromboembolic disease [4,5]. Therefore, therapies
focusing on RV function in PH may improve symptoms, quality
of life, hemodynamics, and survival.
Pharmacological approaches limiting angiotensin II (Ang II)
bioactivity (angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers) are the cornerstone of management of left
ventricular (LV) dysfunction; however, there is no convincing
evidence for use of these therapies in RV failure [6]. Inhibition of a
hyperactive renin angiotensin system provides protection from LV
remodeling, left heart failure, and mortality [7,8,9]. Recently, this
class of therapeutics has expanded to include the novel enzyme,
angiotensin-converting enzyme 2 (ACE2), which converts Ang II
to Ang-(1-7). ACE2 is both present in the circulation and is an
integral membrane protein in 72 organs including the heart
[10,11]. Conversion of Ang II to Ang-(1-7) by ACE2 has anti-
hypertrophic, anti-proliferative, anti-fibrotic, and vasodilator
properties in the LV [12,13,14,15]. In various animal models of
cardiac injury, ACE2 has been shown to be protective [15,16,17].
In an aortic banding model, recombinant human ACE2 (rhACE2)
reversed LV hypertrophy, fibrosis, and improved diastolic
dysfunction [18]. In human patients with left heart failure serum
ACE2 is cardioprotective [19,20].
Although the literature supports a beneficial role for ACE2 in
LV function, the effects of ACE2 specifically on RV function have
not been examined. Importantly, the response of the RV to stress
should not be extrapolated from left heart experiments. The
function, structure, and embryology of the right and left ventricles
are unique. The RV is smaller, crescent shaped, thin-walled, and
has a much lower afterload than the LV [21]; these differences are
augmented by a differing embryologic origin of the RV
[22,23,24,25]. Thus, the RV may not respond similarly to the
LV in response to stress and pharmacological therapies.
In preliminary studies, we demonstrated that ACE2 improves
pulmonary vascular diseasein a transgenicmouse model ofPH, and
now wish to study the effects of ACE2 on RV load-stress responses.
We hypothesized that ACE2 would prevent RV hypertrophy and
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to study pharmaceutical effects of ACE2 on RV dysfunction in
isolation, we administered rhACE2 to pulmonary artery banded
(PAB) mice via osmotic pumps for two weeks. In this PAB model of
early heart failure, we assessed structural, hemodynamic, and
molecular effects of rhACE2 on the RV.
Results
rhACE2 decreases load-induced RV hypertrophy
PAB resulted in significant RV hypertrophy as measured by
RV/LV+Septum (LV+S) ratio that was attenuated with rhACE2
administration (Figure 1). rhACE2 administration without load
stress did not affect RV size. rhACE2 did not affect LV mass in
control or PAB mice. Therefore, rhACE2 prevents load-induced
RV hypertrophy, but has no effect on LV mass. In M-mode
echocardiography, there was significant RV dilation in PAB mice
with a trend (p=0.32) towards decreased RV dilation with
rhACE2 administration.
rhACE2 improves RV systolic and diastolic function
measured by in vivo hemodynamics
The effects of 14 days of PAB or control with or without
rhACE2 exposure on RV hemodynamics were studied (Figure 2).
There were no differences in heart rate between groups
(CON.CON 512622 bpm, ACE2.CON 450619 bpm, CON.-
PAB 475637, ACE2.PAB 525613). PAB resulted in increased
RV peak pressure that is consistent with previously described PAB
model results. PAB increased RV end diastolic pressure, diastolic
time constant, and Ea (arterial elastance, end systolic pressure/
stroke volume). Concomitantly, with PAB, there was a decrease in
ejection fraction (EF). As expected with fixed banding of the
pulmonary artery, administration of rhACE2 to PAB mice did not
affect RV peak pressure. Administration of rhACE2 to control
mice resulted in a small, but statistically significant increase in RV
end diastolic pressure and stroke volume. In PAB mice, rhACE2
significantly decreased RV end diastolic pressure, increased
maximal power, increased EF, increased stroke volume, decreased
time constant, and decreased Ea by two-way ANOVA. In
summary, in the context of PAB, there was improvement in both
systolic and diastolic function with rhACE2.
rhACE2 effect on LV function measured by in vivo
hemodynamics
PAB had no significant effects on LV function in control animals
as measured by in vivo hemodynamics (Figure 3). In PAB mice, there
was a trend towards decreased LV end diastolic pressure with
rhACE2 (p=0.08) though this did not meet statistical significance.
Figure 1. RV hypertrophy is decreased with recombinant human (rhACE2) administration. (A) RV/left ventricle (LV)+septum (S) ratio
demonstrating RV hypertrophy in pulmonary artery banded (PAB) mice that is abrogated by rhACE2. (B) Right ventricular internal dimension in
diastole (RVIDd) measured by M-mode echocardiography in PAB mice and controls with and without rhACE2. (C) There is no change in LV+S with
rhACE2. (D) Representative M-mode echocardiography images with right ventricle labeled RV and RVIDd measured in (a) normal RV (b) CON.PAB and
(c) ACE2.PAB.
doi:10.1371/journal.pone.0020828.g001
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ACE2 is an integral membrane protein present in the left atrium
and LV, but to our knowledge the presence of ACE2 in right heart
tissue has not been documented [10,11]. To confirm the presence
of ACE2 in the RV, we performed immunohistochemistry for
ACE2 using kidney as positive control [10]. ACE2 stained in the
myocardium, epicardium, and endocardium. In Figure 4, panel A
demonstrates ACE2 staining of RV myocardium and endocar-
dium. Panel C confirms ACE2 staining in kidney tissue [10]. Panel
B and panel D depict RV and kidney control tissue not exposed to
ACE2 antibody.
rhACE2 did not diminish RV fibrosis or increase number
of microvessels in PAB model
We explored potential mechanisms by which rhACE2 diminished
RV hypertrophy and improved RV function. There was no
significant change in RV fibrosis between PAB and PAB receiving
rhACE2 (Figure 5) as measured via epicardial, endocardial, or
perivascular fibrosis width (Figure 6). There was also no significant
change in RV fibrosis in PAB compared with PAB receiving rhACE2
as evaluated by percentage of collagen area per area cardiac tissue
(0.6–0.8% CON.CON, 0.3–1% ACE2.CON, 9.3–11.6% CON.-
PAB, and 7.9–21% ACE2.PAB). Since ACE2 stimulates endothelial
cell tube formation [26], we counted the number of microvessels in
the RV. However, the number and size of microvessels was not
different between PAB with and without rhACE2 (Figure 6).
Molecular effects of rhACE2 administration on the RV
Expression of collagen1a1, Mas receptor, and connexin 37 were
measured in RV tissue to determine whether rhACE2 adminis-
tration produced molecular effects on the RV (Figure 7).
Collagen1a1 expression increased around five-fold in PAB mice
(p,0.01) but did not change with rhACE2 administration. In PAB
mice without rhACE2, Mas expression was decreased compared
with controls; rhACE2 administration increased Mas expression in
these mice approximately two-fold (p,0.05). Lastly, connexin 37
was chosen as a marker for cell-cell communication. Connexin 37
is a gap junction protein and is widely distributed in the heart
(cardiac endothelial, epithelial and myocardial cells, conotruncal
ridges, and atrioventricular cushions) [27]. PAB mice had a 24-
fold decrease in connexin 37 expression levels compared with
controls; levels were normalized with rhACE2 administration
(p,0.01).
Discussion
In these experiments, rhACE2 administered via osmotic pumps
to PAB mice for two weeks prevented load-induced RV systolic
and diastolic dysfunction. Importantly, rhACE2 increased power
without increasing RV hypertrophy.
Elevated Ang II levels are instrumental in cardiovascular
remodeling, and therapies limiting Ang II production or binding
are the foundation of cardiovascular therapeutics. Figure 8 depicts
a simplified view of the ACE2 pathway; Angiotensin II is
Figure 2. In vivo hemodynamic measurements in the RV. Long brackets denote effect of PAB p,0.05 by two-way ANOVA, short brackets
denote effect of rhACE2 p,0.05 by two-way ANOVA. PAB decreased markers of systolic function (ejection fraction) and diastolic function (RV end
diastolic pressure, diastolic time constant), and these changes were ameliorated by administration of rhACE2. dPdt max=maximum value of first
derivative of ventricular pressure with respect to time during cardiac cycle. Ea=arterial elastance (end systolic pressure/stroke volume). Values for
max power, ejection fraction, stoke volume, cardiac output, and Ea represent fold change from control.
doi:10.1371/journal.pone.0020828.g002
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Figure 8 also demonstrates that in the heart and vasculature, Ang
II is produced by both mast cell chymase and through
conventional renin-angiotensin pathway conversion of Ang I to
Ang II by angiotensin- converting enzyme (ACE) [28]. Increased
mast cell chymase (present in the secretory granules of mast cells) is
present in cardiac and vascular tissue in animal models of
cardiovascular disease including cardiomyopathy, atherosclerosis,
aortic aneurysm, and myocardial infarction [29,30,31,32,33].
Whereas mast cells are present in the epicardium, endocardium,
Figure 3. In vivo hemodynamic measurements in the LV. On two-way ANOVA, there were no significant findings, though there was a trend
towards decreased LV end diastolic pressure (p=0.08), LV power max, and LV ejection fraction with rhACE2 in PAB. Values represent fold change from
control.
doi:10.1371/journal.pone.0020828.g003
Figure 4. Immunohistochemistry for ACE2. (A) ACE2 stained RV, (B) control RV, (C) ACE2 stained kidney, (D) control kidney. 4006magnification.
doi:10.1371/journal.pone.0020828.g004
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mice, they were only present in the cardiac epicardium and
endocardium in our control animals (not shown). In humans,
higher chymase mRNA expression and mast cell density is present
in failing myocardium compared with controls [34]. Conse-
quently, ACE inhibitors may not effectively suppress Ang II
production, and angiotensin receptor blockers, which inhibit Ang
II binding, do not increase Ang-(1-7) formation. Therefore, ACE2
is a potential treatment option in RV dysfunction, simultaneously
counterbalancing Ang II production in a failing heart and
increasing Ang-(1-7) formation.
Generally, ventricular function improves through increasing
preload, decreasing afterload, or increasing contractility. ACE2
did not increase preload (RV end diastolic volume), nor did it
decrease afterload in our PAB model (the pulmonary vasculature is
dilated at baseline). Consequently, RV improvement with ACE2
administration is likely secondary to improved contractility. There
was significant increase in EF and stroke volume, and there was a
trend towards increased dPdt (maximal initial velocity) with
ACE2. Other studies have linked ACE2 with contractility;
profound contractile dysfunction occurs after ACE2 gene
inactivation in the mouse heart [35]. In an LV ischemic cardiac
model, cardiac overexpression of ACE2 via lenti-virus, produced
results similar to ours; ACE2 did not change collagen density,
cardiomyocyte cross-sectional area, or capillary density in the
ischemia model, yet improved LV wall motion and contractility
[16].
We evaluated molecular effects of ACE2 on the RV by
measuring Mas receptor and connexin expression levels. Review of
the literature suggests that ACE2 may improve LV cardiac
function through Ang-(1-7) activity at the Mas receptor [36,37,38].
In our PAB mice, we demonstrated that Mas expression was
decreased and that Mas expression increased with administration
of rhACE2. The Mas receptor is a G-protein coupled receptor, but
its signaling pathway in the heart is largely unknown. In
preliminary data using a transgenic PAH mouse model, we
Figure 5. RV fibrosis. Masson’s trichrome stain in A) CON.CON B) ACE2.CON 3) CON.PAB 4) ACE2.PAB cardiac tissue. 2006magnification.
doi:10.1371/journal.pone.0020828.g005
Figure 6. Measurement of RV fibrosis. (A) perivascular, (B) epicardial and endocardial fibrosis in the RV. p,0.05 for PAB effect for large brackets.
Number and size of (C) RV microvessels in RV tissue.
doi:10.1371/journal.pone.0020828.g006
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and adherens junctions in whole lung tissue (unpublished). In the
heart, we evaluated intercellular communication through gap
junctions which are assembled from membrane-associated pro-
teins called connexins. Connexin 37 levels were lower in PAB mice
compared with controls and normalized following rhACE2
administration (Figure 7). Therefore, it is possible that ACE2
improves RV function though connexin regulated contractility.
rhACE2 had minimal effect in control animals on echocardio-
graphy and catheterization (administration of rhACE2 to control
mice resulted in a small, but statistically significant increase in RV
end diastolic pressure and stroke volume). Our study did not
examine the underlying mechanisms by which ACE2 may have
affected normal RV function, but changes in normal LV function
have been observed by other investigators with ACE2 [16] which
may represent regulation of this pathway in both normal and
abnormal physiology. In our study, there were no detrimental
effects on the LV in PAB mice receiving rhACE2. In fact, the
trend towards a decrease in LV end diastolic pressure with
rhACE2 correlates with a decrease in RVIDd as visualized by
echocardiography based on cardiac chamber interdependence.
Therefore, in a RV load-stress model of early heart failure,
rhACE2 at a rate of 1.8 mg/kg/day appears to be cardioprotec-
tive in the RV and safe in the LV.
In human PAH patients, ACE2 may provide therapeutic effects
in both the RV and lung. Although the PAB model presented in this
manuscript cannot evaluate distal pulmonary vascular disease,
success in both monocrotaline and transgenic animal models of
PAH support ACE2 as an effective pulmonary vascular treatment.
For example, researchers have prevented pulmonary vascular
disease in a monocrotaline rat model using XNT, a synthetic
activatorofACE2[39].Inaddition,PHwaspreventedandreversed
via gene transfer with ACE2 and Ang-(1-7) lentiviral vectors in
monocrotaline models [40,41]. Our lab administered ACE2 to a
transgenic mouse model of PAH and reversed PH (manuscript in
review). Therefore, ACE2 may provide synergistic therapy in
human PAH patients by improving both RV and lung dysfunction.
Limitations of this study include lack of cardiac conduction
evaluation with electrocardiograms. It has been suggested that
ACE2 transgene overexpression can cause heart block, ventricular
tachycardia, and sudden death [42]. Although Ang-(1-7) benefits
failing hearts by increasing the resting potential, action potential,
and enhancing conduction velocity and electrical synchronization,
anti-arrhythmic properties of Ang-(1-7) are lost at higher levels of
Ang-(1-7) administration [43]. Consequently, rhACE2 may have
differential effects in the heart depending on dose, and further
dosage studies with rhACE2 in heart failure should be performed.
Our PAB model evaluates the early phase of heart failure at a time
point where the heart is capable of compensation. rhACE2 should
also be tested in a chronic pressure-overload model. In the future,
we would like to further examine the molecular etiology behind
rhACE2 therapy in the RV and whether shorter courses of
rhACE2 (3, 5, or 7 days) will result in similar improvement in RV
function.
In summary, RV function is a critical determinant of morbidity
and mortality in PH [2,3]. Therapies targeting RV function may
provide a new class of drugs for RV failure secondary to PH. This
Figure 7. Molecular expression levels in the RV. (A) collagen1a1, (B) Mas receptor, and (C) connexin 37 normalized to HPRT on a log scale. Each
open circle represents one mouse.
doi:10.1371/journal.pone.0020828.g007
Figure 8. The ACE2 pathway.
doi:10.1371/journal.pone.0020828.g008
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pressure overload model in which preventative rhACE2 therapy in
PAB mice improved RV systolic and diastolic dysfunction and
diminished stressed-induced RV hypertrophy.
Methods
Ethics statement
This study was carried out in accordance with the National
Institutes of Health’s Public Health Service Policy of Humane Care
and Use of Laboratory Animals and in accordance with the Animal
Welfare Act. Vanderbilt University Institutional Animal Care and
Use Committee approved all procedures (protocol M/08/083). All
experiments were performed using appropriate analgesics and
anesthetics, and every effort was made to minimize pain and distress.
PAB and pump insertion
Twenty-seven adult male C57BI/6 mice 10 weeks of age
(Jackson Laboratory) were anesthetized with 3% isoflurane,
administered intraperitoneal etomidate (20–40 mL/kg), and
orotracheally intubated. Animals were mechanically ventilated
with isoflurane general anesthesia for PAB or sham surgery. A
sternal incision was made using sterile technique, the pericardium
was removed, and a partially occlusive tantalum clip was placed
around the pulmonary artery (Weck, Research Triangle Park,
NC). The animal was then sutured closed and allowed to recover
from anesthesia. Mice received post-operative analgesic with a
subcutaneous injection of 5 mg/kg of carprofen. Sham treated
animals underwent the same procedure without vascular clip
placement. On post-op day 2, mice were separated into control or
rhACE2 groups: ACE2.PAB n=10, ACE2.CON n=5, CON.-
PAB n=7, CON.CON n=5. The rhACE2 group received
rhACE2 (Apeiron Biologics, Vienna, Austria) at 1.8 mg/kg/day
through micro-osmotic pumps (ALZET 1002). The control group
received vehicle alone (100 mM glycine, 150 mM NaCl, 50 uM
ZnCl2, pH 7.5, Apeiron Biologics). Pumps were placed subcuta-
neously between the scapula using sterile technique. Mice received
analgesic after pump insertion with a subcutaneous injection of
5 mg/kg of carprofen. All assessments were obtained by our
technician who was blinded to rhACE2 or placebo.
Echocardiography
Two-dimensional echocardiography was performed using Vivo
770
 High-Resolution Image System (VisualSonics
 Toronto,
Canada). Echocardiograms were obtained the day prior to
sacrifice under isoflurane anesthetic. In the short axis, left and
right ventricular end systolic and diastolic diameters and heart rate
were recorded in M-mode [44,45].
Measurement of RV pressure
Right ventricular systolic pressure (RVSP) was obtained on all
but one mouse who died prior to RVSP measurement. Two weeks
after receiving rhACE2 or vehicle, mice were anesthetized with
3% isoflurane, administered intraperitoneal etomidate, and
orotracheally intubated. Animals were mechanically ventilated
with vaporized isoflurane general anesthesia. Mice were positioned
supine, ventral side up on a heated operating table. A vertical
incision over the abdomen was made and cautery was used to cut
the diaphragm and expose the heart. RVSP was directly measured
via insertion of a 1.4F Mikro-tip
 catheter into a surgically
exposed heart. Open-chested catheterization was chosen since this
method provides better quality pressure-volume loops than the
close-chested technique in our hands. Hemodynamics were
continuously recorded with a Millar MPVS-300 unit coupled to
a Powerlab 8-SP analog-to-digital converter acquired at 1,000 Hz
and captured to a Macintosh G4 (Millar Instruments Houston,
TX). After obtaining RV measurements, the catheter was removed
and placed into the LV. Mice were sacrificed using a lethal dose of
phenobarbital (Schering-Plough). The right and left heart were
weighed separately and quick-frozen in liquid nitrogen. Several
RV and LV in each group were placed in formalin for histology.
Histology
Antigen retrieval on cardiac tissue was performed with retrievit-
8 (Innogenex, BS-1006-00). Sections were rinsed in DI water and
soaked for 20 minutes in 3% H2O2 (10 ml of H2O2+90 ml
MetOH). Slides were blocked in 10% powerblock (1:10 dilution
universal blocking reagent, Biogenex, HK085-5K) and 0.4%
Triton in PBS and placed in a humid chamber for 15 minutes.
ACE2 (Abcam, ab59351) primary antibody in the presence of
10% powerblock in 0.4% Triton-x 100 in PBS was added 1:200 at
4uC overnight. Secondary antibody (Innogenex, AS-2200-16) anti-
rabbit Igs, biotinylated goat (mouse/rat-absorbed) was applied and
incubated for 20 minutes. Biogenex streptavidin HRP (Innogenex
streptavidin enzyme conjugate CJ-1005-25) was added for
20 minutes. Slides were stained with vector NovaRed (SK-4800)
and counterstained in Mayers hematoxylin. Hearts were also
stained with Masson’s trichrome stain and hematoxylin and eosin.
Epicardial and endocardial fibrosis was quantified by measuring
the width of the three most fibrotic regions per slide. Perivascular
fibrosis was measured on the three most fibrotic vessels on each
slide. Percentage of collagen per cardiac tissue area was obtained
using Nikon NIS-Elements Advanced Research software (Melville,
NY). Microvessels were defined as vessels which were not main
coronary vessels and were identified using immunofluorescence
staining for vWF 1:100 (DAKO, Denmark, A0082). Microvessels
were counted in twenty fields at 4006.
PCR
RNA was obtained using Qiagen RNeasy Mini Kit (Qiagen,
Valencia, CA). First strand cDNA was made using QuantiTectH
Reverse Transcription Kit (Qiagen) from 1 mg total RNA.
Quantitative real-time PCR was performed using a total reaction
volume of 25 ml, containing 5 ml of diluted cDNA, 12.5 ml SYBR
Green Supermix (Applied Biosystems Foster City, CA) and 0.03 ml
of each oligonucleotide primer (250 mM). PCR was carried out in
a StepOnePlus Real Time PCR System (Applied Biosystems) using
40 cycles of 95uC for 15 seconds followed by 60uC for 1 minute
with a ten minute 95uC initial soak. Each measurement was made
in triplicate and expressed relative to the detection of the standard
HPRT. PCR was preformed for the primer sets HPRT,
collagen1a1, Mas1, and connexin 37 (Integrated DNA Technol-
ogies IDTH Coralville, Iowa).
Statistics
Statistical tests were two-way ANOVA with post-hoc Bonferroni
test performed using GraphPad Prism Plus version 5.0 Software
(San Diego, CA). Expression data was log10 transformed before
statistical analyses. A p value ,0.05 was considered significant.
Acknowledgments
We thank Linda Gleaves for histology support. rhACE2 was provided by
Apeiron Biologics.
Author Contributions
Conceived and designed the experiments: JAJ ARH. Performed the
experiments: JAJ KBM. Analyzed the data: JAJ KBM JW ARH.
ACE2 Improves Right Ventricular Function
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20828Contributed reagents/materials/analysis tools: JAJ KBM JW ARH. Wrote
the paper: JAJ KBM JW ARH.
References
1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, et al. (2009)
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:
S43–54.
2. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991)
Survival in patients with primary pulmonary hypertension. Results from a
national prospective registry. Ann Intern Med 115: 343–349.
3. Polak JF, Holman BL, Wynne J, Colucci WS (1983) Right ventricular ejection
fraction: an indicator of increased mortality in patients with congestive heart
failure associated with coronary artery disease. J Am Coll Cardiol 2: 217–224.
4. Ritchie M, Waggoner AD, Davila-Roman VG, Barzilai B, Trulock EP, et al.
(1993) Echocardiographic characterization of the improvement in right
ventricular function in patients with severe pulmonary hypertension after
single-lung transplantation. J Am Coll Cardiol 22: 1170–1174.
5. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, et al. (2007) Reverse
right ventricular remodeling after pulmonary endarterectomy in patients with
chronic thromboembolic pulmonary hypertension: utility of magnetic resonance
imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc
Surg 133: 58–64.
6. Winter MM, Bouma BJ, Groenink M, Konings TC, Tijssen JG, et al. (2009)
Latest insights in therapeutic options for systemic right ventricular failure: a
comparison with left ventricular failure. Heart 95: 960–963.
7. Schmieder RE, Martus P, Klingbeil A (1996) Reversal of left ventricular
hypertrophy in essential hypertension. A meta-analysis of randomized double-
blind studies. JAMA 275: 1507–1513.
8. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., et al. (1992) Effect
of captopril on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival and ventricular
enlargement trial. The SAVE Investigators. N Engl J Med 327: 669–677.
9. SOLVD I (1991) Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. N Engl J Med 325:
293–302.
10. Harmer D, Gilbert M, Borman R, Clark KL (2002) Quantitative mRNA
expression profiling of ACE 2, a novel homologue of angiotensin converting
enzyme. FEBS Lett 532: 107–110.
11. Gallagher PE, Ferrario CM, Tallant EA (2008) Regulation of ACE2 in cardiac
myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295: H2373–2379.
12. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, et al. (2008)
Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on
the heart. Circ Res 103: 1319–1326.
13. Santos RA, Ferreira AJ (2007) Angiotensin-(1-7) and the renin-angiotensin
system. Curr Opin Nephrol Hypertens 16: 122–128.
14. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, et al. (2007) Prevention
of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol
Heart Circ Physiol 292: H736–742.
15. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, et al.
(2007) ACE2 overexpression inhibits hypoxia-induced collagen production by
cardiac fibroblasts. Clin Sci (Lond) 113: 357–364.
16. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, et al. (2008)
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart
from ischemia-induced pathophysiology. Hypertension 51: 712–718.
17. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, et al. (2009) Loss of angiotensin-
converting enzyme 2 accelerates maladaptive left ventricular remodeling in
response to myocardial infarction. Circ Heart Fail 2: 446–455.
18. Zhong J, Basu R, Guo D, Chow FL, Byrns S, et al. (2010) Angiotensin-
converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis,
and cardiac dysfunction. Circulation 122: 717–728, 718 p following 728.
19. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, et al. (2008)
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights
into the endogenous counter-regulatory pathway of the renin-angiotensin-
aldosterone system. J Am Coll Cardiol 52: 750–754.
20. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, et al. (2009) Soluble
angiotensin-converting enzyme 2 in human heart failure: relation with
myocardial function and clinical outcomes. J Card Fail 15: 565–571.
21. Hemnes AR, Champion HC (2008) Right heart function and haemodynamics in
pulmonary hypertension. Int J Clin Pract Suppl. pp 11–19.
22. Kelly RG, Brown NA, Buckingham ME (2001) The arterial pole of the mouse
heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 1:
435–440.
23. Waldo KL, Kumiski DH, Wallis KT, Stadt HA, Hutson MR, et al. (2001)
Conotruncal myocardium arises from a secondary heart field. Development 128:
3179–3188.
24. Mjaatvedt CH, Nakaoka T, Moreno-Rodriguez R, Norris RA, Kern MJ, et al.
(2001) The outflow tract of the heart is recruited from a novel heart-forming
field. Dev Biol 238: 97–109.
25. Dyer LA, Kirby ML (2009) The role of secondary heart field in cardiac
development. Dev Biol 336: 137–144.
26. Lovren F, Pan Y, Quan A, Teoh H, Wang G, et al. (2008) Angiotensin
converting enzyme-2 confers endothelial protection and attenuates athero-
sclerosis. Am J Physiol Heart Circ Physiol 295: H1377–1384.
27. Haefliger JA, Polikar R, Schnyder G, Burdet M, Sutter E, et al. (2000)
Connexin37 in normal and pathological development of mouse heart and great
arteries. Dev Dyn 218: 331–344.
28. Balcells E, Meng QC, Johnson WH, Jr., Oparil S, Dell’Italia LJ (1997)
Angiotensin II formation from ACE and chymase in human and animal hearts:
methods and species considerations. Am J Physiol 273: H1769–1774.
29. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, et al. (2001) Possible roles of
cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol
86: 203–214.
30. Miyazaki M, Takai S, Jin D, Muramatsu M (2006) Pathological roles of
angiotensin II produced by mast cell chymase and the effects of chymase
inhibition in animal models. Pharmacol Ther 112: 668–676.
31. Doggrell SA, Wanstall JC (2004) Vascular chymase: pathophysiological role and
therapeutic potential of inhibition. Cardiovasc Res 61: 653–662.
32. Kaartinen M, Penttila A, Kovanen PT (1994) Mast cells of two types differing in
neutral protease composition in the human aortic intima. Demonstration of
tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty
streaks, and the shoulder region of atheromas. Arterioscler Thromb 14:
966–972.
33. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, et al. (2003) A novel
chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-
benzyl)-4-oxo-a zetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac
fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305: 17–23.
34. Batlle M, Roig E, Perez-Villa F, Lario S, Cejudo-Martin P, et al. (2006)
Increased expression of the renin-angiotensin system and mast cell density but
not of angiotensin-converting enzyme II in late stages of human heart failure.
J Heart Lung Transplant 25: 1117–1125.
35. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, et al. (2002)
Angiotensin-converting enzyme 2 is an essential regulator of heart function.
Nature 417: 822–828.
36. Giani JF, Gironacci MM, Munoz MC, Turyn D, Dominici FP (2008)
Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in
rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and
inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp
Physiol 93: 570–578.
37. Giani JF, Gironacci MM, Munoz MC, Pena C, Turyn D, et al. (2007)
Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat
heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ
Physiol 293: H1154–1163.
38. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, et al. (2008)
Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway
in cardiomyocytes. Hypertension 52: 542–548.
39. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, et al. (2009)
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the
prevention of pulmonary hypertension. Am J Respir Crit Care Med 179:
1048–1054.
40. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, et al. (2009)
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2
gene transfer. Hypertension 54: 365–371.
41. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, et al. (2010) The
ACE2/Ang-(1-7)/Mas Axis Confers Cardiopulmonary Protection against Lung
Fibrosis and Pulmonary Hypertension. Am J Respir Crit Care Med.
42. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, et al. (2003) Heart
block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with
downregulated connexins. J Mol Cell Cardiol 35: 1043–1053.
43. De Mello WC, Ferrario CM, Jessup JA (2007) Beneficial versus harmful effects
of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the
failing heart. J Renin Angiotensin Aldosterone Syst 8: 74–80.
44. Syed F, Diwan A, Hahn HS (2005) Murine echocardiography: a practical
approach for phenotyping genetically manipulated and surgically modeled mice.
J Am Soc Echocardiogr 18: 982–990.
45. Collins KA, Korcarz CE, Lang RM (2003) Use of echocardiography for the
phenotypic assessment of genetically altered mice. Physiol Genomics 13:
227–239.
ACE2 Improves Right Ventricular Function
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20828